Title :

A new paradigm in managing advanced ovarian cancer: differentiating patients requiring neoadjuvant treatment from primary cytoreduction

Author(s) :

Kraus, Francois [Auteur]
CHU Amiens-Picardie
El Hajj, Houssein [Auteur]
Institut Paoli-Calmettes [IPC]
Le Deley, Marie-Cecile [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Aissaoui, Othman [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Gachon, Bertrand [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Chevalier, Annick [Auteur]
Abdeddaim, Cyril [Auteur]
Université de Lorraine [UL]
Lemaire, Anne-Sophie [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Ben Haj Amor, Mariem [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Sylla, Dienabou [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Leblanc, Eric [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Narducci, Fabrice [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Hudry, Delphine [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Journal title :

Cancers

Abbreviated title :

Cancers (Basel)

Volume number :

13

Pages :

4925

Publication date :

2021-09-30

ISSN :

2072-6694

Keyword(s) :

propensity score
primary cytoreduction
advanced ovarian cancer
neoadjuvant chemotherapy
interval debulking surgery

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Our study aims to evaluate the comparability of primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) patients. This single-center retrospective study includes all patients treated for advanced stages high-grade ...
Show more >Our study aims to evaluate the comparability of primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) patients. This single-center retrospective study includes all patients treated for advanced stages high-grade serous ovarian carcinomas (HGSOC) between 2007 and 2017. Preoperative characteristics and postoperative outcomes were compared after a propensity score matching analysis. Of the 221 patients included, 38% underwent PDS, and 62% received NACT. There was no age difference at diagnosis; however, CA125 levels, PCI score levels, and rates of stage IV were higher in the NACT group. There were no differences concerning the rate and the severity of complications (p = 0.29). The propensity score distribution showed a broad distinction between PDS patients and NACT patients with no significant overlap. Survival analyses demonstrate, after a median follow-up of 66.5 months, an overall survival (OS) of 105.9 and progression-free survival (PFS) of 29.2 months in the PDS group, compared to OS of 52.8 and PFS of 18.9 months in the NACT group. Advanced HGSOC is a heterogeneous population, in which inoperable patients should be differentiated from PDS patients based on many factors, primarily tumor burden.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

INSERM
Université de Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T14:00:52Z
2023-01-11T09:43:02Z